Roche has obtained a CE Mark in the EU for a companion diagnostic that can be used to identify patients with HER2-low metastatic breast cancer who may be eligible for treatment with AstraZeneca and Daiichi Sankyo’s Enhertu.
Copyright © 2024 | WordPress Theme by MH Themes